Daisuke Morishita

Company: Chordia Therapeutics

Job title: Co-Founder & Chief Scientific Officer

Seminars:

CTX-439: A First-in-Class Orally Available CDK12 Inhibitor with Anti- Tumor Potential 8:30 am

Analyzing CTX-439's selective inhibition of CDK12 and its impact on transcription elongation, leading to aberrant RNA accumulation and increased cancer cell stress Evaluating the preclinical anti-tumor efficacy of CTX-439 in various carcinoma mouse models, assessing its potential as an effective single-agent therapy Exploring the synergistic effects of combining CTX-439 with PARP inhibitors or chemotherapeutic agents,…Read more

day: Day Two